Literature DB >> 1782077

ras p21 expression in relation to DNA ploidy, S-phase fraction and prognosis in colorectal adenocarcinoma.

X F Sun1, S Wingren, J M Carstensen, O Stål, T Hatschek, B Boeryd, B Nordenskjöld, H Zhang.   

Abstract

ras p21 expression, as indicated by the monoclonal antibody ras 11, was estimated using immunohistochemistry on 69 primary colorectal adenocarcinomas. Also, DNA ploidy and S-phase fraction (SPF) were analysed with flow cytometry. Positive staining for ras 11 tended to be more common in DNA non-diploid tumours (P = 0.11), but was significantly correlated with high SPF (P = 0.038). Positive ras 11 staining, Dukes' stage, DNA ploidy and SPF were related to the recurrence-free interval of patients with Dukes' A-C tumours (P = 0.0014, P = 0.023, P = 0.035 and P = 0.040, respectively). ras 11 staining was a prognostic factor independent of both Dukes' stage and DNA ploidy (P = 0.011). The results indicate that pan ras p21 expression is associated with proliferative activity and has an independent prognostic value in colorectal adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1782077     DOI: 10.1016/0277-5379(91)90437-i

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  4 in total

1.  Prognostic significance of p53 expression in relation to DNA ploidy in colorectal adenocarcinoma.

Authors:  X F Sun; J M Carstensen; O Stål; H Zhang; E Nilsson; R Sjödahl; B Nordenskjöld
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

2.  Variables related to risk of recurrence in rectal cancer without lymph node metastasis.

Authors:  H Ogiwara; T Nakamura; S Baba
Journal:  Ann Surg Oncol       Date:  1994-03       Impact factor: 5.344

3.  Tumour markers of prognosis in colorectal cancer.

Authors:  H L McLeod; G I Murray
Journal:  Br J Cancer       Date:  1999-01       Impact factor: 7.640

4.  Overexpression of wild-type p21Ras plays a prominent role in colorectal cancer.

Authors:  Shuang Bai; Qiang Feng; Xin-Yan Pan; Hong Zou; Hao-Bin Chen; Peng Wang; Xin-Liang Zhou; Yan-Ling Hong; Shu-Ling Song; Ju-Lun Yang
Journal:  Int J Mol Med       Date:  2017-02-21       Impact factor: 4.101

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.